Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
JAVELIN PARP MEDLEY
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
- NCT03330405 ↗
- Terminated
- Pfizer
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on JAVELIN PARP MEDLEY (avelumab plus talazoparib in locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on JAVELIN PARP MEDLEY so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Interventions
- Avelumab Phase 1b; Talazoparib Phase 1b; Avelumab Phase 2; Talazoparib Phase 2
- Arms
- Dose Level 0 Phase 1b · Experimental
- Dose Level -1 Phase 1b · Experimental
- Dose Level -2 Phase 1b · Experimental
- A1. NSCLC Phase 2 · Experimental
- A2. NSCLC PD-L1 Resistant DDR+ Phase 2 · Experimental
- B1. TNBC Phase 2 · Experimental
- B2. HR+BC DDR Defect +Assay Phase 2 · Experimental
- C1. Ovarian CA Recurrent Plat-Sensitive Phase 2 · Experimental
- C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2 · Experimental
- D.Urothelial CA Phase 2 · Experimental
- E1. CRPC Phase 2 · Experimental
- E2. CRPC DDR Defect +Assay Phase 2 · Experimental
- F: Advanced Solid Tumors with BRCA or ATM defect Phase 2 · Experimental
- Enrollment
- 223
- Primary outcomes
- Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs)
- Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment
- Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) by Investigator Assessment
- Sponsor
- Pfizer
- Start
- Oct 19, 2017
- Primary completion
- Feb 22, 2022
- Results posted
- Yes
- Registry record
- NCT03330405 · updated Oct 13, 2023
Publications
linked from the registry- Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol. 2023 Jan 1;9(1):40-50. doi: 10.1001/jamaoncol.2022.5228. PubMed 36394849